Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 18;9(7):1721.
doi: 10.3390/cells9071721.

Engineering CD4+ T Cells to Enhance Cancer Immunity

Francesca Sillito  1 , Angelika Holler  2 , Hans J Stauss  2
Affiliations
Review

Engineering CD4+ T Cells to Enhance Cancer Immunity

Francesca Sillito et al. Cells. .

Abstract

This review presents key advances in combining T cell receptor (TCR) gene transfer to redirect T-cell specificity with gene engineering in order to enhance cancer-protective immune function. We discuss how emerging insights might be applied to CD4+ T cells. Although much attention has been paid to the role of CD8+ cytotoxic T cells in tumour protection, we provide convincing evidence that CD4+ helper T cells play a critical role in cancer immune responses in animal models and also in patients. We demonstrate that genetic engineering technologies provide exciting opportunities to extend the specificity range of CD4+ T cells from MHC class-II-presented epitopes to include peptides presented by MHC class I molecules. Functional enhancement of tumour immunity can improve the sensitivity of T cells to cancer antigens, promote survival in a hostile tumour microenvironment, boost cancer-protective effector mechanisms and enable the formation of T-cell memory. Engineered cancer-specific CD4+ T cells may contribute to protective immunity by a direct pathway involving cancer cell killing, and by an indirect pathway that boosts the function, persistence and memory formation of CD8+ T cells.

Keywords: T cell receptor (TCR); T helper cell (Th); interferon-gamma (IFN-γ); major histocompatibility complex (MHC); mechanistic target of Rapamycin 1 (mTORC1); programmed death receptor 1 (PD-1).

PubMed Disclaimer

Conflict of interest statement

H.J.S. has shares in Cell Medica and Quell Therapeutic. He is also an adviser to Quell. He also received research funding from ”Apollo Therapeutics”.

References

    1. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2001;2:957–961. doi: 10.1038/ni1001-957. - DOI - PubMed
    1. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2001;2:962–970. doi: 10.1038/ni1001-962. - DOI - PubMed
    1. Provasi E., Genovese P., Lombardo A., Magnani Z., Liu P.Q., Reik A., Chu V., Paschon D.E., Zhang L., Kuball J., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012;18:807–815. doi: 10.1038/nm.2700. - DOI - PMC - PubMed
    1. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821. doi: 10.1126/science.1225829. - DOI - PMC - PubMed
    1. Schober K., Muller T.R., Gokmen F., Grassmann S., Effenberger M., Poltorak M., Stemberger C., Schumann K., Roth T.L., Marson A., et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 2019;3:974–984. doi: 10.1038/s41551-019-0409-0. - DOI - PubMed

Publication types